Oramed Pharmaceuticals (ORMP) Total Non-Current Liabilities (2011 - 2026)
Oramed Pharmaceuticals (ORMP) posted Total Non-Current Liabilities of $20.0 million for Q1 2026, up 66.26% on a QoQ basis from $12.0 million in Q4 2025, and up 829.31% year-over-year from $2.2 million in Q1 2025.
Oramed Pharmaceuticals (ORMP) Total Non-Current Liabilities (2011 - 2026) Analysis & Trends
Oramed Pharmaceuticals' Total Non-Current Liabilities history runs 16 years deep, the most recent figure standing at $20.0 million for Q1 2026.
- Quarterly Total Non-Current Liabilities rose 829.31% year-over-year to $20.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $20.0 million (up 829.31% YoY) and the FY2025 annual result came in at $12.0 million, up 183.42% from the prior year.
- Total Non-Current Liabilities was $20.0 million for Q1 2026 at Oramed Pharmaceuticals, up from $12.0 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $20.0 million in Q1 2026 and bottomed at $2.2 million in Q1 2025.
- A 5-year average of $6.0 million and a median of $4.4 million in 2023 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2025 — Total Non-Current Liabilities slumped 50.79% — and 2026, when it jumped 829.31%.
- Oramed Pharmaceuticals' Total Non-Current Liabilities stood at $4.7 million in 2022, then dropped by 6.24% to $4.4 million in 2023, then retreated by 4.46% to $4.2 million in 2024, then surged by 183.42% to $12.0 million in 2025, then soared by 66.26% to $20.0 million in 2026.
- Business Quant data shows ORMP's Total Non-Current Liabilities at $20.0 million in Q1 2026, $12.0 million in Q4 2025, and $12.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | Oramed Pharmaceuticals | 170.25 Mn | 170.25 Mn | - | 20.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 20.01 Mn |
| Dec 31, 2025 | 12.03 Mn |
| Sep 30, 2025 | 12.04 Mn |
| Jun 30, 2025 | 4.41 Mn |
| Mar 31, 2025 | 2.15 Mn |
| Dec 31, 2024 | 4.25 Mn |
| Sep 30, 2024 | 4.29 Mn |
| Jun 30, 2024 | 4.34 Mn |
| Mar 31, 2024 | 4.38 Mn |
| Dec 31, 2023 | 4.44 Mn |
| Sep 30, 2023 | 4.49 Mn |
| Jun 30, 2023 | 4.59 Mn |
| Mar 31, 2023 | 4.66 Mn |
| Dec 31, 2022 | 4.74 Mn |
| Sep 30, 2022 | 4.77 Mn |
| Jun 30, 2022 | 2.84 Mn |
| Mar 31, 2022 | 3.68 Mn |
| Nov 30, 2021 | 4.10 Mn |
| Aug 31, 2021 | 4.80 Mn |
| May 31, 2021 | 5.55 Mn |